Fingolimod

Results: 83



#Item
11SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medici

SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medici

Add to Reading List

Source URL: www.scottishmedicines.org.uk

Language: English
12SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medici

SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medici

Add to Reading List

Source URL: www.scottishmedicines.org.uk

Language: English
13Pharmacology / Medicine / Natalizumab / Alemtuzumab / Fingolimod / Clinical trial / Immunosuppressants / Immunology / Multiple sclerosis

7.10 ALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). Purpose of Application

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-03-16 01:05:14
14Public Summary Document – November 2014 PBAC MeetingALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). 1

Public Summary Document – November 2014 PBAC MeetingALEMTUZUMAB solution for infusion, 10 mg/ mL; Lemtrada®; Genzyme (Sanofi-Aventis Australia Pty Ltd). 1

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-03-16 01:05:14
15Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx

Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-04-22 23:39:46
16Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI PROTECT WP5 IMI Report 2:b:iv NATALIZUMAB WAVE 2 CASE STUDY REPORT Review of methodologies for benefit and

Add to Reading List

Source URL: protectbenefitrisk.eu

Language: English - Date: 2014-07-16 01:09:14
17Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI WP5 Report 1:b:iv Benefit-Risk Wave 1 case study report: NATALIZUMAB Risk benefit case study with a focus on testing methodology.

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium IMI WP5 Report 1:b:iv Benefit-Risk Wave 1 case study report: NATALIZUMAB Risk benefit case study with a focus on testing methodology.

Add to Reading List

Source URL: protectbenefitrisk.eu

Language: English - Date: 2014-07-16 01:09:12
18Submission on Authority Required Medicines for the Post-market Review of Authority Required PBS Listings ® Gilenya (fingolimod) October 2014

Submission on Authority Required Medicines for the Post-market Review of Authority Required PBS Listings ® Gilenya (fingolimod) October 2014

Add to Reading List

Source URL: pbs.gov.au

Language: English - Date: 2015-03-02 18:33:43
19Scottish Medicines Consortium Minutes of the SMC Meeting held on Tuesday 05 August 2014 The Lighthouse, 11 Mitchell Lane, Glasgow G1 3NU Present:

Scottish Medicines Consortium Minutes of the SMC Meeting held on Tuesday 05 August 2014 The Lighthouse, 11 Mitchell Lane, Glasgow G1 3NU Present:

Add to Reading List

Source URL: www.scottishmedicines.org.uk

Language: English
20Drug Utilisation Sub-Committee Outcome Statement 6-7 June 2013 The Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) held its 78th meeting on 6-7 June[removed]DUSC is a national

Drug Utilisation Sub-Committee Outcome Statement 6-7 June 2013 The Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) held its 78th meeting on 6-7 June[removed]DUSC is a national

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-03-13 00:20:02